Government issues advisory on GLP-1 drugs, warns against misuse

The Government of India has released a detailed note on GLP-1 drugs, highlighting their growing use in treating type 2 diabetes and obesity, while also warning about potential risks and misuse. As these medicines gain popularity, especially for weight loss, the authorities have stepped up monitoring and regulation to ensure patient safety.

The advisory comes amid rising demand for these drugs in India, with reports of easy availability through online platforms and wellness clinics.

Officials have now made it clear that GLP-1 drugs are not general wellness products but powerful prescription medicines that must only be used under expert supervision.

WHAT ARE GLP-1 DRUGS AND WHY ARE THEY USED?

GLP-1 (Glucagon-Like Peptide-1) drugs are a class of medicines used to manage blood sugar levels in people with type 2 diabetes. They also help in weight loss by slowing digestion and reducing appetite.

These drugs work by mimicking a natural hormone in the body that increases insulin release and lowers excess glucose. Because of their dual benefit of controlling diabetes and aiding weight loss, they have become increasingly popular in recent years.

GOVERNMENT WARNS OF SERIOUS SIDE EFFECTS

The government has cautioned that GLP-1 drugs can cause serious side effects if taken without proper medical advice. These may include digestive issues, hormonal imbalance, and other complications if misused.

Health experts stress that these medicines are not suitable for everyone and should not be used casually for weight loss without proper



diagnosis and supervision.

PRESCRIPTION ONLY: WHO CAN RECOMMEND THESE DRUGS?

According to the advisory, GLP-1 drugs can only be prescribed by qualified medical specialists such as endocrinologists, internal medicine experts, and cardiologists.

They are strictly not available over the counter. The government has warned people against purchasing these drugs online or from unauthorised sellers without a valid prescription.

STRICT ACTION AGAINST VIOLATIONS

The Drug Controller General of India (DCGI), along with State Drug Controllers, has intensified surveillance across the country. Inspections are being carried out at pharmacies, clinics, and online platforms.

Authorities have clearly stated that any violation, such as illegal sale or misuse, will lead to strict action, including licence cancellation, fines, and legal proceedings.

RISING DEMAND TRIGGERS TIGHTER CONTROL

The increased popularity of GLP-1 drugs, especially for weight loss, has raised concerns about their misuse. While they offer medical benefits, experts warn against viewing them as quick-fix solutions.

The government’s latest move aims to strike a balance, ensuring access for genuine patients while preventing unsafe and unregulated use.

As GLP-1 drugs become more widely used, the government’s advisory serves as an important reminder: these are powerful medications, not lifestyle products. Proper medical guidance, awareness of risks, and strict regulation will be key to ensuring their safe use in India.